Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease-Reference-Cited by-同舟云学术

Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease

Published:2019-05-09 Issue:8 Volume:14 Page:1259-1270
ISSN:1828-0447
Container-title:Internal and Emergency Medicine
language:en
Short-container-title:Intern Emerg Med

Author:

Godino Cosmo, ,Melillo Francesco,Rubino Francesca,Arrigoni Luca,Cappelletti Alberto,Mazzone Patrizio,Mattiello Paolo,Della Bella Paolo,Colombo Antonio,Salerno Anna,Cera Michela,Margonato Alberto

Publisher

Springer Science and Business Media LLC

Subject

Emergency Medicine,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11739-019-02100-9.pdf

Reference41 articles.

1. Das M, Aronow WS, McClung JA, Belkin RN (2006) Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 14:14–17. https://doi.org/10.1097/01.crd.0000148162.88296.9f

2. Nelson SE, Shroff GR, Li S, Herzog CA (2012) Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc 1:1–11. https://doi.org/10.1161/JAHA.112.002097

3. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation:the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369. https://doi.org/10.1161/CIRCULATIONAHA.108.816082

4. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, Breithardt G (2009) Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20:705–711. https://doi.org/10.1681/ASN.2007111207

5. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB (2015) Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. J Am Coll Cardiol 64:2471–2482. https://doi.org/10.1016/j.jacc.2014.09.051

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs);The American Journal of Cardiology;2023-11

2. Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (≥85 years old) with non-valvular atrial fibrillation;Minerva Medica;2023-04

3. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial;European Heart Journal - Cardiovascular Pharmacotherapy;2022-11-07

4. Renal function and mortality in patients with atrial fibrillation;Journal of Cardiovascular Medicine;2022-06-23

5. Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset;BMC Nephrology;2021-12